Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.

Autor: Merdrignac L; Epidemiology Department, Epiconcept, Paris, France., Laniece Delaunay C; Epidemiology Department, Epiconcept, Paris, France., Verdasca N; National Reference Laboratory for Influenza Virus and Other Respiratory Viruses, Infectious Disease Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Vega-Piris L; National Centre of Epidemiology, CIBERESP, Carlos III Health Institute, Madrid, Spain., O'Donnell J; Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland., Sève N; Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, Paris, France., Trobajo-Sanmartín C; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain., Buda S; Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany., Hooiveld M; Nivel, Utrecht, the Netherlands., Rodrigues AP; Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Túri G; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Latorre-Margalef N; Department of microbiology, Public Health Agency of Sweden, Stockholm, Sweden., Mlinarić I; Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health, Zagreb, Croatia., Lazar M; National Influenza Centre, Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania., Maurel M; Epidemiology Department, Epiconcept, Paris, France., Castrillejo D; Servicio de Vigilancia Epidemiológica, Dirección General de Salud Pública, Consejería de Políticas Sociales y Salud Pública, Melilla, Spain., Bennett C; National Virus Reference Laboratory, University College Dublin, Dublin, Ireland., Rameix-Welti MA; Centre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France.; Molecular Mechanisms of Multiplication of Pneumovirus Unit, UMR 1173 (2I), Institut Pasteur, Université Paris-Saclay, Université de Versailles St. Quentin, INSERM, Université Paris Cité, Paris, France., Martínez-Baz I; Instituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain., Dürrwald R; National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany., Meijer A; National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands., Melo A; National Reference Laboratory for Influenza Virus and Other Respiratory Viruses, Infectious Disease Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Oroszi B; National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary., Hagey TS; Department of microbiology, Public Health Agency of Sweden, Stockholm, Sweden., Kurečić Filipović S; Division for Epidemiology of Communicable Diseases, Croatian Institute of Public Health, Zagreb, Croatia., Dijkstra F; National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands., Gomez V; Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal., Bacci S; Vaccine Preventable Diseases and Immunisation Section, European Centre for Disease Prevention and Control, Stockholm, Sweden., Kaczmarek M; Vaccine Preventable Diseases and Immunisation Section, European Centre for Disease Prevention and Control, Stockholm, Sweden., Kissling E; Epidemiology Department, Epiconcept, Paris, France.
Jazyk: angličtina
Zdroj: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Nov; Vol. 18 (11), pp. e70009.
DOI: 10.1111/irv.70009
Abstrakt: We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.
(© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje